-
2
-
-
67649596590
-
-
National Cancer Institute. Available From [last accessed 4 Nov 2013]
-
National Cancer Institute. Probability of breast cancer in American women. Available from: Http://www.cancer.gov/ cancer topics/ factsheet/Detection/Probability-breast-cancer [last accessed 4 Nov 2013
-
Probability of Breast Cancer in American Women
-
-
-
3
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: Globocan 2008
-
Frlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127: 2893-917
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Frlay, J.1
Shin, H.R.2
Bray, F.3
-
4
-
-
46049089154
-
-
National Cancer Institute. Available From [last accessed 4 Nov 2013]
-
National Cancer Institute. Breast cancer. Available from: Http:// www.cancer.gov/cancertopics/types/breast [last accessed 4 Nov 2013
-
Breast Cancer
-
-
-
5
-
-
79851486664
-
Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
-
James R, Thrivenik K, krishnamoorthy L, et al. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer. Indian J Med Res 2011;133:70-5
-
(2011)
Indian J Med Res
, vol.133
, pp. 70-75
-
-
James, R.1
Thrivenik, K.2
Krishnamoorthy, L.3
-
6
-
-
34147105901
-
Cross-Talk between er and her 2 in breast carcinoma
-
Natasha TR Zora K, Dragica NV. Cross-Talk between ER and Her 2 in breast carcinoma. Arch Oncol 2006;14:146-50
-
(2006)
Arch Oncol
, vol.14
, pp. 146-150
-
-
Natasha, T.R.1
Zora, K.2
Dragica, N.V.3
-
7
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12. (Pubitemid 19147683
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
Levin, W.J.7
Stuart, S.G.8
Udove, J.9
Ullrich, A.10
Press, M.F.11
-
8
-
-
56949108012
-
Her2-Positive breast cancer: Herceptin and beyond
-
Dean-Colomb W, Esteva FJ. Her2-Positive breast cancer: Herceptin and beyond. Eur J Cancer 2008;44:2806-12
-
(2008)
Eur J Cancer
, vol.44
, pp. 2806-2812
-
-
Dean-Colomb, W.1
Esteva, F.J.2
-
9
-
-
0034018946
-
Laboratory assessment of the status of her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
-
10.1136/jcp.53.5.374
-
Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens:comparision of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374-81. (Pubitemid 30256906
-
(2000)
Journal of Clinical Pathology
, vol.53
, Issue.5
, pp. 374-381
-
-
Wang, S.1
Saboorian, M.H.2
Frenkel, E.3
Hynan, L.4
Gokaslan, S.T.5
Ashfaq, R.6
-
10
-
-
0034864813
-
Her2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer
-
Menard S,Casalini P, Campiglio M, et al. Her2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001;12:S15-19
-
(2001)
Ann Oncol
, vol.12
-
-
Menard, S.1
Casalini, P.2
Campiglio, M.3
-
11
-
-
0022406444
-
Amplification of a novel v-erbB-related gene in a human mammary carcinoma
-
King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb B-related gene in a human mammary Carcinoma. Science 1985; 229:974-6. (Pubitemid 16248488
-
(1985)
Science
, vol.229
, Issue.4717
, pp. 974-976
-
-
King, C.R.1
Kraus, M.H.2
Aaronson, S.A.3
-
12
-
-
0034766736
-
Biology of her2 and its importance in breast cancer
-
Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61:1-13. (Pubitemid 33033419
-
(2001)
Oncology
, vol.61
, Issue.SUPPL. 2
, pp. 1-13
-
-
Yarden, Y.1
-
13
-
-
0032875428
-
Basic science of her-2/neu: A review
-
Hung MC, Lau Y-K. Basic Science of HER 2/neu: A review. Semin Oncol 1999;26:51-9. (Pubitemid 29411433
-
(1999)
Seminars in Oncology
, vol.26
, Issue.4 SUPPL. 12
, pp. 51-59
-
-
Hung, M.-C.1
Lau, Y.-K.2
-
14
-
-
0023640312
-
Proto-oncogenes and humancancers
-
Slamon DJ. Proto-oncogenes and humancancers. N Engl J Med 1987;317:955-7
-
(1987)
N Engl J Med
, vol.317
, pp. 955-957
-
-
Slamon, D.J.1
-
15
-
-
0030974096
-
Neuregulin-2, a new ligand of erbb3/erbb4-receptor tyrosine kinases
-
10.1038/387512a0
-
Carraway KL III, Weber JL, Unger MJ, et al. Neuregulin-2 a new ligand of erbB3/erbB4-receptor tyrosine kinase. Nature 1997;387: 512-16. (Pubitemid 27235470
-
(1997)
Nature
, vol.387
, Issue.6632
, pp. 512-516
-
-
Carraway III, K.L.1
Weber, J.L.2
Unger, M.J.3
Ledesma, J.4
Yu, N.5
Gassmann, M.6
Lai, C.7
-
16
-
-
0025374582
-
Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and pI 85 protein expression in human breast cancer cell lines
-
Linnea DR, Duane KJ, Dennis JS, Benita SK. Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and pI 85 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947-51
-
(1990)
Cancer Res
, vol.50
, pp. 3947-3951
-
-
Linnea, D.R.1
Duane, K.J.2
Dennis, J.S.3
Benita, S.K.4
-
17
-
-
0030944455
-
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
-
10.1093/emboj/16.7.1647
-
Graus-Porta D, Beerli RR, Dalya JM, Hynes NE. ErbB-2 the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55. (Pubitemid 27151960
-
(1997)
EMBO Journal
, vol.16
, Issue.7
, pp. 1647-1655
-
-
Graus-Porta, D.1
Beerli, R.R.2
Daly, J.M.3
Hynes, N.E.4
-
18
-
-
0037429725
-
The ErbB receptors and their role in cancer progression
-
10.1016/S0014-4827(02)00099-X
-
Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. (Pubitemid 36331969
-
(2003)
Experimental Cell Research
, vol.284
, Issue.1
, pp. 99-110
-
-
Holbro, T.1
Civenni, G.2
Hynes, N.E.3
-
19
-
-
44149098849
-
Cytogenetic analysis of HER 1/EGFR, HER 2, HER 3, and HER 4 in 278 breast cancer patients
-
Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER 1/EGFR, HER 2, HER 3, and HER 4 in 278 breast cancer patients. Breast Cancer Res 2008;10:R2
-
(2008)
Breast Cancer Res
, vol.10
-
-
Sassen, A.1
Rochon, J.2
Wild, P.3
-
20
-
-
58149260228
-
Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma a systematic review
-
Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma. A systematic review. Radiother Oncol 2009;90:1-13
-
(2009)
Radiother Oncol
, vol.90
, pp. 1-13
-
-
Offersen, B.V.1
Overgaard, M.2
Kroman, N.3
Overgaard, J.4
-
21
-
-
50249085041
-
Patient choice significantly affects mastectomy rates in the treatment of breast cancer
-
Kirby RM, Basit A, Manimaran N. Patient choice significantly affects mastectomy rates in the treatment of breast cancer. Int Semin Surg Oncol 2008;5:20-2
-
(2008)
Int Semin Surg Oncol
, vol.5
, pp. 20-22
-
-
Kirby, R.M.1
Basit, A.2
Manimaran, N.3
-
22
-
-
71249086867
-
Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2X2 randomised clinical trial in patients with low risk of recurrence
-
German Breast Cancer Study Group (GBSG).
-
Winzer KJ, Sauerberi W, Braun M, et al. German Breast Cancer Study Group (GBSG). Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2X2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010;46:95-101
-
(2010)
Eur J Cancer
, vol.46
, pp. 95-101
-
-
Winzer, K.J.1
Sauerberi, W.2
Braun, M.3
-
23
-
-
78650293742
-
Ipsilateral breast recurrence after breast conserving surgery in patients with small (-cm) breast cancer treated with modern adjuvant therapies
-
Siponen ET, Vaalavirata L, Joensuu H, et al. Ipsilateral breast recurrence after breast conserving surgery in patients with small (-cm) breast cancer treated with modern adjuvant therapies. Eur J Surg Oncol 2011;37:15-31
-
(2011)
Eur J Surg Oncol
, vol.37
, pp. 15-31
-
-
Siponen, E.T.1
Vaalavirata, L.2
Joensuu, H.3
-
24
-
-
0028857587
-
Breast and ovarian cancer-specific cytotoxic t lymphocytes recognize the same her2/neu-derived peptide
-
Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-Derived peptide. Proc Natl Acad Sci USA 1995;92: 432-6
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 432-436
-
-
Peoples, G.E.1
Goedegebuure, P.S.2
Smith, R.3
-
25
-
-
0037102126
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a north american trial
-
Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a north american trial. J Clin Oncol 2002;20:3386-95
-
(2002)
J Clin Oncol
, vol.20
, pp. 3386-3395
-
-
Osborne, C.K.1
Pippen, J.2
Jones, S.E.3
-
26
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
10.1056/NEJMoa053028
-
Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20. (Pubitemid 43290919
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.8
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.-L.2
Bono, P.3
Alanko, T.4
Kataja, V.5
Asola, R.6
Utriainen, T.7
Kokko, R.8
Hemminki, A.9
Tarkkanen, M.10
Turpeenniemi-Hujanen, T.11
Jyrkkio, S.12
Flander, M.13
Helle, L.14
Ingalsuo, S.15
Johansson, K.16
Jaaskelainen, A.-S.17
Pajunen, M.18
Rauhala, M.19
Kaleva-Kerola, J.20
Salminen, T.21
Leinonen, M.22
Elomaa, I.23
Isola, J.24
more..
-
27
-
-
0029956081
-
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
-
10.1038/nm0796-811
-
Aas T, Børresen A-L, Geisler S, et al. Specific P53 mutations are associated withde novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-14. (Pubitemid 26225099
-
(1996)
Nature Medicine
, vol.2
, Issue.7
, pp. 811-814
-
-
Aas, T.1
Borresen, A.-L.2
Geisler, S.3
Smith-Sorensen, B.4
Johnsen, H.5
Varhaug, J.E.6
Akslen, L.A.7
Lonning, P.E.8
-
28
-
-
0031444312
-
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
-
Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881-6. (Pubitemid 28009824
-
(1997)
Journal of the National Cancer Institute
, vol.89
, Issue.24
, pp. 1881-1886
-
-
Ahmad, N.1
Feyes, D.K.2
Nieminen, A.-L.3
Agarwal, R.4
Mukhtar, H.5
-
29
-
-
0031734394
-
Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
-
Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. JCO November 1998;11:3502-8. (Pubitemid 28506760
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.11
, pp. 3502-3508
-
-
Ryberg, M.1
Nielsen, D.2
Skovsgaard, T.3
Hansen, J.4
Jensen, B.V.5
Dombernowsky, P.6
-
30
-
-
0031663593
-
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
-
Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93
-
(1998)
Clin Cancer Res
, vol.4
, pp. 2089-2093
-
-
Geisler, J.1
King, N.2
Anker, G.3
-
31
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
10.1056/NEJMoa064320
-
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355: 2733-43. (Pubitemid 46021510
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
32
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-And/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
-
Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbb-1-And/or erbb-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16. (Pubitemid 32880059
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.18
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Mauriac, L.4
Llombert-Cussac, A.5
Janicke, F.6
Miller, W.R.7
Evans, D.B.8
Dugan, M.9
Brady, C.10
Quebe-Fehling, E.11
Borgs, M.12
-
33
-
-
0036091354
-
HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil
-
Di Leo A, Gancberg D, Larsimont D, et al. HER-2 Amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16. (Pubitemid 34517647
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.5
, pp. 1107-1116
-
-
Di Leo, A.1
Gancberg, D.2
Larsimont, D.3
Tanner, M.4
Jarvinen, T.5
Rouas, G.6
Dolci, S.7
Leroy, J.-Y.8
Paesmans, M.9
Isola, J.10
Piccart, M.J.11
-
34
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
35
-
-
33645278071
-
The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters
-
Zhouy Z-T, Yangy Y, Ge J-P. The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis 2006;27:826-32
-
(2006)
Carcinogenesis
, vol.27
, pp. 826-832
-
-
Zhouy, Z.-T.1
Yangy, Y.2
Ge, J.-P.3
-
36
-
-
84883045013
-
Antitumor activity of tak-285, an investigational, non-pgp substrate her2/egfr kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an her2-positive brain metastasis model
-
Nakayama A, Takagi S, Yusa T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer 2013;4: 557-65
-
(2013)
J Cancer
, vol.4
, pp. 557-565
-
-
Nakayama, A.1
Takagi, S.2
Yusa, T.3
-
37
-
-
33847773775
-
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
-
10.1093/jnci/djk050
-
Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trial. JNCI J Natl Cancer Inst 2007;99:283-90. (Pubitemid 47073491
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.4
, pp. 283-290
-
-
Powles, T.J.1
Ashley, S.2
Tidy, A.3
Smith, I.E.4
Dowsett, M.5
-
38
-
-
84860363447
-
Evaluation of her-2/ neu status in breast cancer specimens using immunohistochemistry (ihc) & fluorescence in-situ hybridization (fish) assay
-
Goud KI, Dayakar S, Vijayalaxmi K, et al. Evaluation of HER-2/ neu status in breast cancer specimens using Immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res 2012;135:312-17
-
(2012)
Indian J Med Res
, vol.135
, pp. 312-317
-
-
Goud, K.I.1
Dayakar, S.2
Vijayalaxmi, K.3
|